United States securities and exchange commission logo

                             August 11, 2020

       Nello Mainolfi, Ph.D.
       President and Chief Executive Officer
       Kymera Therapeutics, Inc.
       300 Technology Square, 2nd Floor
       Cambridge, MA 02139

                                                        Re: Kymera
Therapeutics, Inc.
Statement on Form S-1
                                                            Filed July 31, 2020
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed August 5,
                                                            File No. 333-240264

       Dear Dr. Mainolfi:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1

       Prospectus Summary
       Overview, page 1

   1.                                                   Refer to comment 2. The
products in your discovery pipeline are not sufficiently
                                                        advanced or under your
control to emphasize in the pipeline table. Revise to eliminate the
                                                        discovery pipeline.
   2.                                                   Refer to comment 3.
Revise the pipeline to include individual columns for Phases 2 and
                                                        3, or tell us on what
basis you believe you will be able to combine your Phase 2 and 3
                                                        studies for all of the
product candidates listed in this table.
 Nello Mainolfi, Ph.D.
Kymera Therapeutics, Inc.
August 11, 2020
Page 2
3.     Refer to comment 4. Revise the pipeline table to clearly distinguish
between the
       application for which you will seek regulatory approval for KT-474. In
doing so, explain
       or delete the reference to "others."
Risk Factors
Risks Related to Intellectual Property, page 46

4.     We note your response to comment 8. As you take the position Kymera will
not be
       required to change its name, revise to add a risk factor specifically
outlining the risks if
       you are unable to trademark Kymera in the United States. Expand on your
disclosure that
       you "may not be able to compete effectively and [y]our business may be
Business Overview, page 100

5.     Refer to comment 13. You continue to describe your potential products as
potent on
       pages 1, 81, 99, 103 and elsewhere. Revise these and all similar
statements in the
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

        You may contact Vanessa Robertson at (202) 551-3649 or Daniel Gordon at
(202) 551-
3486 if you have questions regarding the financial statements and related
matters. Please contact
Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other

FirstName LastNameNello Mainolfi, Ph.D.
                                                             Division of
Corporation Finance
Comapany NameKymera Therapeutics, Inc.
                                                             Office of Life
August 11, 2020 Page 2
cc:       William D. Collins, Esq.
FirstName LastName